[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital of Macerata\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":64},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":20,"conditions":21,"keywords":23,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100531496",false,"NCT06200558","ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa","Inclusion Criteria:\n\n* Patients aged \\>18y\n* Cytological or Histologically confirmed diagnosis of PC\n* Histologically or radiologically confirmed diagnosis of metastatic disease and\n\nFor ARON-3S\n\n▪ Treatment with ADT + Apalutamide or ADT + enzalutamide or ADT + Abiraterone or ADT + Abiraterone + Docetaxel or ADT + Darolutamide + Docetaxel (patients treated with previous docetaxel - CHAARTED - resulted eligible)\n\nFor ARON-3Lu\n\n▪ Treatment with Luthetium-177-PSMA therapy for castration resistant PC\n\nFor ARON-3GEN\n\n* HRD POSITIVE STATUS\n* Treatment with PARP inhibitors for castration resistant PC. Treatment included: olaparib (as 1st, 2nd or 3rd line therapy), olaparib + abiraterone (as 1st line therapy) or niraparib + abiraterone (as 1st line therapy) or talazoparib + enzalutamide\n\nExclusion Criteria:\n\n* Patients without histologically confirmed diagnosis of PC\n* Patients without histologically or radiologically confirmed metastatic disease and\n\nFor ARON-3S\n\n▪ Patients treated with doublets or triplets not included in the list reported in the Inclusion Criteria Section\n\nFor ARON-3Lu\n\n▪ Patients treated with Luthetium-177-PSMA therapy for hormone\u002Fcastration sensitive PC\n\nFor ARON-3GEN\n\n* HRD NEGATIVE STATUS\n* Patients treated with PARP inhibitors alone or in combination regimens not included in the ARON-3GEN study","ALL","18 Years",{"count":17,"type":18},534,"ESTIMATED","OBSERVATIONAL","Study wants to explore real-world data in three distinct settings\n\n* Patients with metachronous or de novo mCSPC treated with ADT+ARSI or ADT+ARSI+docetaxel \\_ARON-3S\n* Patients receiving Lutetium-177 PSMA for mCRPC \\_ ARON-3Lu\n* Patients treated with PARP inhibitors (alone or combined with ARSI) for CRPC \\_ ARON-3GEN",[22],"Prostate Cancer",[24,25,26,27,28],"mCSPC","Lutetium-177 PSMA","PARP inhibitors","ADT","ARSI","RECRUITING","2025-11-19",{"date":32,"type":33},"2025-11-26","ACTUAL",{"date":35,"type":33},"2024-01-31",{"date":37,"type":18},"2028-02-01",{"name":39,"class":40},"Hospital of Macerata","OTHER",1,{"id":43,"slug":4,"hasResults":10,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":41},"100461347","NCT05287464","International Multicentric Study ARON-1","Inclusion Criteria:\n\n* Patients aged \\>18y\n* Cytological or Histologically confirmed diagnosis of clear cell or non-clear cell RCC\n* Histologically or radiologically confirmed diagnosis of metastatic disease\n* First-line treatment with nivolumab plus ipilimumab or nivolumab plus cabozantinib or pembrolizumab plus axitinib or pembrolizumab plus lenvatinib or avelumab plus axitinib or atezolizumab plus bevacizumab\n\nExclusion Criteria:\n\n* Patients without histologically confirmed diagnosis of RCC\n* Patients without histologically or radiologically confirmed metastatic disease\n* Patients treated with immuno-combinations not included in the list reported in the Inclusion Criteria Section",{"count":48,"type":18},1220,"The ARON-1 Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of immuno-combinations in patients with metastatic RCC.\n\nTwo Supplementary Studies (ARON-1α and ARON-1β) have been designed. The ARON-1α Supplementary Study has been designed to investigate for the presence of genomic signatures from tumor samples of patients treated with first-line immuno-combinations for advanced RCC. The ARON-1β Supplementary Study has been designed to charaterize the immune cell populations and assess their relationship with the clinical outcome of mRCC patients treated with first-line immuno-combinations",[51],"Metastatic Renal Cell Carcinoma (mRCC)",[53,54,55,56,57],"immunotherapy","mRCC","immuno-combinations","artificial intelligence technology","real-world data",{"date":32,"type":33},{"date":60,"type":33},"2022-03-10",{"date":62,"type":18},"2027-09-30",{"name":39,"class":40},""]